000277727 001__ 277727
000277727 005__ 20250406001046.0
000277727 0247_ $$2doi$$a10.1002/mds.30112
000277727 0247_ $$2pmid$$apmid:39797511
000277727 0247_ $$2pmc$$apmc:PMC11926504
000277727 0247_ $$2ISSN$$a0885-3185
000277727 0247_ $$2ISSN$$a1531-8257
000277727 0247_ $$2altmetric$$aaltmetric:172933777
000277727 037__ $$aDZNE-2025-00448
000277727 041__ $$aEnglish
000277727 082__ $$a610
000277727 1001_ $$0P:(DE-2719)9002627$$aQuattrone, Andrea$$b0$$udzne
000277727 245__ $$aProspective Multicenter Evaluation of the MDS 'Suggestive of PSP' Diagnostic Criteria.
000277727 260__ $$aNew York, NY$$bWiley$$c2025
000277727 3367_ $$2DRIVER$$aarticle
000277727 3367_ $$2DataCite$$aOutput Types/Journal article
000277727 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1743593399_11065
000277727 3367_ $$2BibTeX$$aARTICLE
000277727 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000277727 3367_ $$00$$2EndNote$$aJournal Article
000277727 520__ $$aThe recent Movement Disorders Society (MDS)-progressive supranuclear palsy (PSP) diagnostic criteria conceptualized three clinical diagnostic certainty levels: 'suggestive of PSP' for sensitive early diagnosis based on subtle clinical signs, 'possible PSP' balancing sensitivity and specificity, and 'probable PSP' highly specific for PSP pathology.The aim of this study was to prospectively validate the criteria against long-term clinical follow-up and characterize the diagnostic certainty increase over time.Patients with 'possible PSP' or 'suggestive of PSP' diagnosis and clinical follow-up were recruited in two German multicenter longitudinal observational studies (ProPSP and DescribePSP). The cumulative percentage of patients longitudinally increasing diagnostic certainty was assessed over up to 2.5 years of follow-up. The sample size per arm required to detect 30% attenuated rate in diagnostic certainty increase in trials was estimated over multiple time intervals.Of 254 patients with available longitudinal data, 61 patients had low diagnostic certainty at baseline (48 suggestive of PSP, 13 possible PSP) and multiple clinical visits (median: 3, range: 2-4). The cumulative percentage of patients increasing diagnostic certainty progressed with follow-up duration (30.4% at 6 months, 51.7% at 1 year, 80.4% at 2.5 years). The sample size required to detect 30% reduction in diagnostic certainty increase rate within 1 year was 163, slightly smaller than that required using the PSP rating scale.Most 'suggestive of PSP' patients increased diagnostic certainty upon longitudinal follow-up, providing the first prospective multicenter validation of MDS-PSP diagnostic criteria. Our data support the design of trials tailored for these early-stage patients, suggesting the PSP rating scale and the diagnostic certainty increase rate as potential endpoint measures. © 2025 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
000277727 536__ $$0G:(DE-HGF)POF4-353$$a353 - Clinical and Health Care Research (POF4-353)$$cPOF4-353$$fPOF IV$$x0
000277727 588__ $$aDataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
000277727 650_7 $$2Other$$adiagnostic criteria
000277727 650_7 $$2Other$$alongitudinal
000277727 650_7 $$2Other$$aprogressive supranuclear palsy
000277727 650_7 $$2Other$$asuggestive of PSP
000277727 650_7 $$2Other$$avalidation
000277727 650_2 $$2MeSH$$aHumans
000277727 650_2 $$2MeSH$$aSupranuclear Palsy, Progressive: diagnosis
000277727 650_2 $$2MeSH$$aFemale
000277727 650_2 $$2MeSH$$aMale
000277727 650_2 $$2MeSH$$aAged
000277727 650_2 $$2MeSH$$aMiddle Aged
000277727 650_2 $$2MeSH$$aLongitudinal Studies
000277727 650_2 $$2MeSH$$aProspective Studies
000277727 650_2 $$2MeSH$$aSensitivity and Specificity
000277727 650_2 $$2MeSH$$aAged, 80 and over
000277727 693__ $$0EXP:(DE-2719)DESCRIBE-PSP-20160101$$5EXP:(DE-2719)DESCRIBE-PSP-20160101$$eDZNE Clinical Registry Study of Neurodegenerative Diseases in Patients with Progressive Supranuclear Paresis (PSP)$$x0
000277727 7001_ $$aFranzmeier, Nicolai$$b1
000277727 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b2$$udzne
000277727 7001_ $$0P:(DE-2719)2810273$$aPetzold, Gabor C$$b3$$udzne
000277727 7001_ $$0P:(DE-2719)2811324$$aSpottke, Annika$$b4$$udzne
000277727 7001_ $$0P:(DE-2719)2810593$$aBrosseron, Frederic$$b5$$udzne
000277727 7001_ $$0P:(DE-2719)2814178$$aFalkenburger, Björn$$b6$$udzne
000277727 7001_ $$0P:(DE-2719)2380559$$aPrudlo, Johannes$$b7$$udzne
000277727 7001_ $$0P:(DE-2719)2320009$$aGasser, Thomas$$b8$$udzne
000277727 7001_ $$aDESCRIBE-PSP Group, The ProPSP Group$$b9$$eCollaboration Author
000277727 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter U$$b10$$eLast author$$udzne
000277727 7001_ $$0P:(DE-2719)2810273$$aPetzold, Gabor C$$b11$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)9002382$$aKimmich, Okka$$b12$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)2814178$$aFalkenburger, Björn$$b13$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)9001016$$aDinter, Elisabeth$$b14$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)2811373$$aHöglinger, Günter$$b15$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)9000852$$aPalleis, Carla$$b16$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)9002620$$aBernhardt, Alexander Maximilian$$b17$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)2811659$$aLevin, Johannes$$b18$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)9001160$$aKatzdobler, Sabrina$$b19$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)9002626$$aJäck, Alexander$$b20$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)2380559$$aPrudlo, Johannes$$b21$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)2320009$$aGasser, Thomas$$b22$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)2811916$$aBrockmann, Kathrin$$b23$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)2811324$$aSpottke, Annika$$b24$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)9001536$$aGamez, Anna$$b25$$eContributor$$udzne
000277727 7001_ $$0P:(DE-2719)2810593$$aBrosseron, Frederic$$b26$$eContributor$$udzne
000277727 7001_ $$aKlietz, Martin$$b27$$eContributor
000277727 7001_ $$aWegner, Florian$$b28$$eContributor
000277727 7001_ $$aPötter-Nerger, Monika$$b29$$eContributor
000277727 7001_ $$aPedrosa, David J$$b30$$eContributor
000277727 7001_ $$aEggers, Carsten$$b31$$eContributor
000277727 7001_ $$0P:(DE-2719)9001340$$aMollenhauer, Brit$$b32$$eContributor$$udzne
000277727 7001_ $$aClaus, Inga$$b33$$eContributor
000277727 7001_ $$aRegensburger, Martin$$b34$$eContributor
000277727 7001_ $$aSüß, Patrick$$b35$$eContributor
000277727 7001_ $$aWarnecke, Tobias$$b36$$eContributor
000277727 7001_ $$aGandor, Florin$$b37$$eContributor
000277727 7001_ $$aGruber, Doreen$$b38$$eContributor
000277727 7001_ $$0P:(DE-2719)2000059$$aBerg, Daniela$$b39$$eContributor
000277727 7001_ $$aPaschen, Steffen$$b40$$eContributor
000277727 7001_ $$aClaßen, Joseph$$b41$$eContributor
000277727 7001_ $$0P:(DE-2719)9001967$$aKassubek, Jan$$b42$$eContributor$$udzne
000277727 7001_ $$aJost, Wolfgang H$$b43$$eContributor
000277727 7001_ $$aTönges, Lars$$b44$$eContributor
000277727 773__ $$0PERI:(DE-600)2041249-6$$a10.1002/mds.30112$$gVol. 40, no. 3, p. 526 - 536$$n3$$p526 - 536$$tMovement disorders$$v40$$x0885-3185$$y2025
000277727 8564_ $$uhttps://pub.dzne.de/record/277727/files/DZNE-2025-00448%20SUP.zip
000277727 8564_ $$uhttps://pub.dzne.de/record/277727/files/DZNE-2025-00448.pdf$$yOpenAccess
000277727 8564_ $$uhttps://pub.dzne.de/record/277727/files/DZNE-2025-00448.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000277727 909CO $$ooai:pub.dzne.de:277727$$pdnbdelivery$$pdriver$$pVDB$$popen_access$$popenaire
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002627$$aExternal Institute$$b0$$kExtern
000277727 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811659$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000277727 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810273$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b3$$kDZNE
000277727 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811324$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b4$$kDZNE
000277727 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2810593$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b5$$kDZNE
000277727 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2814178$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b6$$kDZNE
000277727 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2380559$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b7$$kDZNE
000277727 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2320009$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b8$$kDZNE
000277727 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2811373$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b10$$kDZNE
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2810273$$aExternal Institute$$b11$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002382$$aExternal Institute$$b12$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2814178$$aExternal Institute$$b13$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001016$$aExternal Institute$$b14$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811373$$aExternal Institute$$b15$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9000852$$aExternal Institute$$b16$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002620$$aExternal Institute$$b17$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811659$$aExternal Institute$$b18$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001160$$aExternal Institute$$b19$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9002626$$aExternal Institute$$b20$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2380559$$aExternal Institute$$b21$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2320009$$aExternal Institute$$b22$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811916$$aExternal Institute$$b23$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2811324$$aExternal Institute$$b24$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001536$$aExternal Institute$$b25$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)2810593$$aExternal Institute$$b26$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001340$$aExternal Institute$$b32$$kExtern
000277727 9101_ $$0I:(DE-HGF)0$$6P:(DE-2719)9001967$$aExternal Institute$$b42$$kExtern
000277727 9131_ $$0G:(DE-HGF)POF4-353$$1G:(DE-HGF)POF4-350$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lNeurodegenerative Diseases$$vClinical and Health Care Research$$x0
000277727 9141_ $$y2025
000277727 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2024-12-16
000277727 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2024-12-16
000277727 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2024-12-16
000277727 915__ $$0LIC:(DE-HGF)CCBYNCND4$$2HGFVOC$$aCreative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
000277727 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOVEMENT DISORD : 2022$$d2024-12-16
000277727 915__ $$0StatID:(DE-HGF)3001$$2StatID$$aDEAL Wiley$$d2024-12-16$$wger
000277727 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2024-12-16
000277727 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2024-12-16
000277727 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2024-12-16
000277727 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000277727 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2024-12-16
000277727 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bMOVEMENT DISORD : 2022$$d2024-12-16
000277727 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2024-12-16
000277727 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2024-12-16
000277727 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz$$d2024-12-16$$wger
000277727 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2024-12-16
000277727 9201_ $$0I:(DE-2719)1111015$$kClinical Research (Munich)$$lClinical Research (Munich)$$x0
000277727 9201_ $$0I:(DE-2719)1111016$$kAG Levin$$lClinical Neurodegeneration$$x1
000277727 9201_ $$0I:(DE-2719)1013020$$kAG Petzold$$lVascular Neurology$$x2
000277727 9201_ $$0I:(DE-2719)1011103$$kAG Spottke$$lClinical Research Platform (CRP)$$x3
000277727 9201_ $$0I:(DE-2719)1011303$$kAG Heneka$$lNeuroinflammation, Biomarker$$x4
000277727 9201_ $$0I:(DE-2719)1710012$$kAG Falkenburger$$lTranslational Parkinson Research$$x5
000277727 9201_ $$0I:(DE-2719)1510100$$kAG Teipel$$lClinical Dementia Research (Rostock /Greifswald)$$x6
000277727 9201_ $$0I:(DE-2719)1210000$$kAG Gasser$$lParkinson Genetics$$x7
000277727 980__ $$ajournal
000277727 980__ $$aVDB
000277727 980__ $$aUNRESTRICTED
000277727 980__ $$aI:(DE-2719)1111015
000277727 980__ $$aI:(DE-2719)1111016
000277727 980__ $$aI:(DE-2719)1013020
000277727 980__ $$aI:(DE-2719)1011103
000277727 980__ $$aI:(DE-2719)1011303
000277727 980__ $$aI:(DE-2719)1710012
000277727 980__ $$aI:(DE-2719)1510100
000277727 980__ $$aI:(DE-2719)1210000
000277727 9801_ $$aFullTexts